Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055653 · ClinicalTrials.gov registry record · Phase 2
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00055653: Completed Phase 2 study, sponsored by Roswell Park Cancer Institute.
NCT00055653 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055653, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG busulfan
- DRUG cyclosporine
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00055653 record still lists
NCT00055653 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00055653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00055653 about?
NCT00055653 is a clinical study titled "Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders". RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating pati...
What is the current status of trial NCT00055653?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00055653?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055653?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia